Source - LSE Regulatory
RNS Number : 6656Y
ReNeuron Group plc
10 September 2020
 

 

 

10 September 2020                                                                                       AIM: RENE

 

ReNeuron Group plc

("ReNeuron" or the "Company")

 

Result of AGM

 

ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, announces that all resolutions put to shareholders at its Annual General Meeting ("AGM") held earlier today were duly passed.

 

The details of proxy voting are being made available in the investor section of the Company's website, http://www.reneuron.com/investors/general-meeting/.

 

Following completion of the AGM, the Company has entered into a relationship agreement with Obotritia Capital KGaA, as indicated in the Company's announcement of 12 August 2020, to ensure that the Company is capable of carrying on its business independently at all times.

 

ENDS

 

ENQUIRIES:

 

ReNeuron

+44 (0) 20 3819 8400

Olav Hellebø , Chief Executive Officer


Michael Hunt, Chief Financial Officer


 

Buchanan (Media/Investor relations)

 

+44 (0) 20 7466 5000

Mark Court, Tilly Abraham




Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)

Ben Maddison, Stewart Wallace

+44 (0) 20 7710 7600

N+1 Singer (Joint Broker)

Aubrey Powell, James Moat, Tom Salvesen

 

+44 (0) 20 7496 3000

 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs.  The Company's clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke.  

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain.  The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGKKKBPQBKDOCD
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.